<DOC>
	<DOC>NCT00724529</DOC>
	<brief_summary>The purpose of this study is to understand the safety and effectiveness of infliximab when used in clinical practice. This is a post-marketing surveillance study.</brief_summary>
	<brief_title>Post Marketing Surveillance of Remicade</brief_title>
	<detailed_description>The investigator will record continuously from the first patient since the day of contract to the numbers of patients of contract based on Remicade approval.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Severe active Crohn's disease: the patients with severe active Crohn's disease who do not show any response to the treatment with corticosteroid or immunosuppressive agents, have no drug tolerance, or are contraindicated to such treatments. Fistulatype active Crohn's disease: the patients with fistulatype active Crohn's disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant. Ankylosing spondylitis: the patients with ankylosing spondylitis who do not show adequate response to general treatments, and with increased serological indices related to severe axial symptoms and inflammation.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>